Séminaire de Recherche : Geoffroy Gagliardi


Geoffroy Gagliardi, Ph.D. student, Institut du Cerveau et de la Moelle Epinière et Institut de la Mémoire et de la Maladie d'Alzheimer, Hôpital de la Salpêtrière. Title: The Memory Binding Test (MBT) : a new tool for the Episodic Memory Assessment in subjects with Preclinical Alzheimer’s Disease. Abstract: Alzheimer’s disease (AD) is classically define as a neurodegenerative disease which is clinically characterized at the forefront by a progressive episodic memory impairment — defined as an amnestic syndrome of the hippocampus type —, associated or not with another cognitive impairment (e.g. executive functioning, attentional difficulties), and ultimately all cognitive spheres affected. Since several years, it has been shown that the pathologic biological markers of AD develops during a long period before the onset of the first clinical symptoms, and especially brain amyloidosis has been associated with subtle cognitive decline in at risk for AD population. A preclinical stage has thus been defined as the presence of (at least) one biomarker of AD in cognitively normal people and a possible cognitive decline insufficient to be qualified as clinical AD nor Mild Cognitive Impairment (MCI). Indeed, available memory tests, do not seems to be sensitive or challenging enough to detect subtle memory decline at preclinical stage of AD. In our study, we used the Memory Binding Test (MBT), specifically conceived to detect early memory changes in AD in subjects with subjective memory decline (SMD) to evaluate the possible correlation between the test outcome and the patients’ level of brain amyloidosis, as measured with PET.